Business / Finance

RSS

SAFC, Oncolytics Biotech sign commercial supply agreement for REOLYSIN

Oncolytics Biotech Inc. today announced that it has entered into a commercial supply agreement with SAFC, a Division of Sigma-Aldrich Corporation, for the commercial manufacture of REOLYSIN, Oncolytics proprietary reovirus.

11 May 2011

TSO3 first quarter revenue decreases to $136,628

TSO3 Inc. an innovator in sterilization technology for medical devices in healthcare settings, posted revenues of $136,628 for the first quarter of 2011 ending March 31, for the sale of supplies, accessories and service contracts for the first generation product.

11 May 2011

Naurex announces completion of $18 million Series A financing

Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today announced the completion of an $18 million Series A financing led by Adams Street Partners and Latterell Venture Partners.

11 May 2011

Pacira Pharmaceuticals reports net loss of $9.8 million for first quarter 2011

Pacira Pharmaceuticals, Inc., an emerging specialty pharmaceutical company, today announced financial results for the first quarter ended March 31, 2011, provided an update on the execution of its pre-commercial and launch strategies for EXPAREL, and reiterated 2011 financial guidance.

11 May 2011

Thermo Fisher Scientific to acquire all outstanding shares of Dionex for $118.50

Thermo Fisher Scientific, the world leader in serving science, is confident in being able to secure all necessary outstanding regulatory and antitrust approvals in connection with its previously announced tender offer to acquire all of the outstanding shares of Dionex Corporation for $118.50 per share in cash.

From Thermo Fisher Scientific Inc. 11 May 2011

U.S. biopharmaceutical companies to benefit from Almac's European Product Launch workshop

Almac is hosting its inaugural European Product Launch workshop in Boston, MA on 17th May 2011. Targeted specifically at the biopharmaceutical sector, the workshop provides consultative advice and services to US companies to successfully launch drug products onto the European market.

11 May 2011

Inovio first quarter total revenue increases to $3.1 million for 2011

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended March 31, 2011.

11 May 2011

EMD Millipore inaugurates new Shanghai Biopharmaceutical Technical Center

EMD Millipore, the Life Science division of Merck KGaA of Germany, today opened its state-of-the-art Biopharmaceutical Technical and Training Center in Shanghai, China. The 28,000 square foot facility will provide support, training and validation services to EMD Millipore's biopharmaceutical customers with operations in China.

11 May 2011

Tenet rejects Community Health's 'best and final' offer

Hospital operator Tenet Healthcare Corp. on Monday rejected Community Health Systems Inc.'s latest buyout offer, which had been increased by about 21 percent. Community's latest offer had been set to expire Monday and had said the latest proposal represented its final offer. Tenet says the offer still undervalues the company.

11 May 2011

Allos, Mundipharma enter strategic collaboration to co-develop FOLOTYN

Allos Therapeutics, Inc. and Mundipharma International Corporation Limited today jointly announced that the companies have entered into a strategic collaboration agreement to co-develop FOLOTYN (pralatrexate injection).

11 May 2011

China Sky One Medical first quarter total revenue decreases 1.9% to $28.4 million

China Sky One Medical, Inc., a leading fully integrated pharmaceutical company in the People's Republic of China, today announced financial results for the first quarter of 2011.

11 May 2011

Micromet first quarter total revenues decrease to $5.5 million

Micromet, Inc., a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced its financial results for the first quarter ended March 31, 2011.

10 May 2011

Roper Industries signs definitive agreement to acquire Northern Digital

Roper Industries, Inc. today announced that it has signed a definitive agreement to acquire Northern Digital, Inc., a leading provider of 3-D measurement technology for medical applications. Northern Digital will become part of Roper's medical platform.

10 May 2011

Insmed first quarter revenues decrease to $1.6 million

Insmed Incorporated, a biopharmaceutical company, today reported results for the first quarter ended March 31, 2011.

10 May 2011

Simcere first quarter total revenue increases 5.1% to RMB482.2 million

Simcere Pharmaceutical Group, a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China, today reported unaudited financial results for the first quarter ended March 31, 2011.

10 May 2011

Inspire reports net loss of $17.6 million for first quarter 2011

Inspire Pharmaceuticals, Inc. announced today financial results for the first quarter ended March 31, 2011, reporting a net loss of $17.6 million or per common share, as compared to a net loss of $14.8 million, or per common share, for the same period in 2010.

10 May 2011

CorMedix first quarter net loss decreases to $1.9 million

CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, today announced its financial results for the quarter ended March 31, 2011.

10 May 2011

EpiCept first quarter net loss decreases to $2.5 million

EpiCept Corporation today announced operating and financial results for the three months ended March 31, 2011, and provided an update with respect to the Company's key business initiatives.

10 May 2011

OncoGenex first quarter revenue decreases to $1.2 million

OncoGenex Pharmaceuticals, Inc. today announced its first quarter financial results and provided an update on current events and activities.

10 May 2011

Osiris Therapeutics net income increases to $4.0 million for first quarter 2011

Osiris Therapeutics, Inc., the leading stem cell company focused on developing and marketing products to treat medical conditions in the inflammatory, autoimmune, cardiovascular, wound care and orthopedic areas, announced today its results for the first quarter ended March 31, 2011.

10 May 2011